Ashakiran Sunku, MD
Neurology with Special Qualifications in Child Neurology · Pueblo, CONPI 1174603005
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.7% of the total across 163 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.9% — the pattern of someone who eats at a lot of different presentations.
Across 163 payments — averaging $21.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$671
- Novartis$331
- SK Life Science, Inc.$287
- AbbVie$248
- Biogen$168
- Argenx US, Inc.$151
- plus $2K from 30 others
What the payments were for
- Speaking & faculty fees$471%
- Food & beverage$3,50199%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 27 | $671 |
| Novartis | 18 | $331 |
| SK Life Science, Inc. | 11 | $287 |
| AbbVie | 12 | $248 |
| Biogen | 9 | $168 |
| Argenx US, Inc. | 6 | $151 |
| Sanofi | 7 | $148 |
| Tanabe Pharma America, Inc. | 5 | $103 |
| EMD Serono, Inc. | 4 | $94 |
| Pfizer | 5 | $92 |
| Lilly USA, LLC | 4 | $91 |
| Amneal Pharmaceuticals LLC | 4 | $87 |
| Kyowa Kirin, Inc. | 4 | $86 |
| TG Therapeutics, Inc. | 3 | $77 |
| AstraZeneca | 4 | $77 |
| Genentech USA, Inc. | 3 | $69 |
| Mallinckrodt Hospital Products Inc. | 3 | $68 |
| Eisai Inc. | 3 | $65 |
| Amgen | 3 | $65 |
| Avion Pharmaceuticals | 3 | $64 |
| ANI Pharmaceuticals, Inc. | 2 | $58 |
| Acadia Pharmaceuticals Inc | 3 | $57 |
| Livanova USA, Inc. | 2 | $51 |
| Abbott | 2 | $49 |
| Acorda Therapeutics, Inc | 2 | $47 |
| Cycle Pharmaceuticals Inc | 2 | $44 |
| Neurelis, Inc. | 2 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $27 |
| Banner Life Sciences, LLC | 1 | $21 |
| Scilex Pharmaceuticals Inc. | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 1 | $16 |
| Merz Pharmaceuticals, LLC | 1 | $15 |
| Genentech, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
| Avanir Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$3,548 in reported general payments places this provider in the 85th percentile of 41 neurology with special qualifications in child neurology providers in Colorado.
See all neurology with special qualifications in child neurology providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Avonex (4 Pack)Interferon Beta-1a | 13 | $108,335 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 12 | $100,002 |
| Glatiramer Acetate | 32 | $92,847 |
| CopaxoneGlatiramer Acetate | 15 | $87,480 |
| BetaseronInterferon Beta-1b | 13 | $85,668 |
| XcopriCenobamate | 56 | $63,832 |
| GlatopaGlatiramer Acetate | 23 | $47,507 |
| KeppraLevetiracetam | 14 | $32,724 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 455 | $17,502 |
| Dalfampridine ErDalfampridine | 37 | $16,183 |
| Rivastigmine | 45 | $13,633 |
| Levetiracetam | 383 | $12,766 |
| Memantine Hcl | 378 | $11,321 |
| TrileptalOxcarbazepine | 11 | $10,674 |
| Lacosamide | 112 | $9,966 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| BiogenAvonex (4 Pack) | $168 | $108,33513 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $30 | $87,48015 claims |
| SK Life Science, Inc.Xcopri | $287 | $63,83256 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $87 | $2,18245 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 41 neurology with special qualifications in child neurology providers in Colorado.
Other neurology with special qualifications in child neurology in Pueblo
- Julie ParsonsAurora$178K
- Melissa CirilloColorado Springs$97K
- Michele YangAurora$15K
- Timothy BenkeAurora$9K
- Ryan KammeyerAurora$4K
- Teri SchreinerAurora$3K
- Marcy YonkerAurora$3K
- Katharine MeddlesDenver$2K
- Jessica LitwinAurora$2K
- Jennifer ArmstrongAurora$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.